

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074194 A2

- (51) International Patent Classification⁷: **A61F** (74) Agent: **GOLLIN, Michael, A.**; Venable, Baetjer, Howard & Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000, P.O. Box 34385, Washington, DC 20043-9998 (US).
- (21) International Application Number: **PCT/US02/08039**
- (22) International Filing Date: **18 March 2002 (18.03.2002)** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/276,089 16 March 2001 (16.03.2001) **US**
- (71) Applicant (*for all designated States except US*): **STS BIOPOLYMERS, INC.** [US/US]; 336 Summit Point Drive, P.O. Box 349, Henrietta, NY 14467 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **WHITBOURNE, Richard, J.** [US/US]; 2500 East Avenue, Rochester, NY 14610 (US). **CHAMBERLAIN, Alexandra, M.** [US/US]; 50 Dierdre Drive, Rochester, NY 14617 (US). **HULLIHEN, Daniel, G.** [US/US]; 5763 Sutton Road, Apt. 2, Avon, NY 14414 (US). **ROSEBROUGH, Scott, F.** [US/US]; 90 Lake Road, Avon, NY 14414 (US). **CALISTRI-YEH, Mildred** [US/US]; 495 Pellett Road, Webster, NY 14580 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **MEDICATED MULTI-LAYER POLYMER COATING**



(57) Abstract: This invention relates to stents having medicated multi-layer hybrid polymer coatings, useful for the treatment of stenosed vasculature or other body passages.

WO 02/074194 A2

BEST AVAILABLE COPY

MEDICATED MULTI-LAYER POLYMER COATING**FIELD OF THE INVENTION**

This invention relates to stents having medicated multi-layer hybrid polymer
5 coatings, useful for the treatment of stenosed vasculature or other body passages.

BACKGROUND OF THE INVENTION

Angioplasty procedures have dramatically increased as a treatment for occluded
arteries. However, vessels often experience reclosure following the angioplasty procedure.
The closure of vessels following angioplasty is known as restenosis. The process of
10 restenosis can occur in over 30% of the cases, depending upon the vessel location, lesion
length, as well as other variables.

Restenosis may be caused in some cases by simple mechanical reflex; e.g. caused by
the elastic rebound of the arterial wall and/or by dissections in the vessel wall caused by the
angioplasty procedure. These mechanical problems have been mitigated somewhat by the
15 use of stents to hold open and prevent elastic rebound of the vessel, and reducing the level of
restenosis for many patients. The stent is typically introduced by catheter into a vascular
lumen and expanded into contact with the stenosed vascular lesion, thereby providing
internal support for the vessel wall. Examples of stents, which have been used in the clinics
include stents disclosed in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882
20 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor which are incorporated
herein by reference in their entirety.

Another aspect of restenosis is believed to be a natural healing reaction to the injury
of the arterial wall that is caused by the angioplasty procedure. The final result of the
complex steps of the healing process is intimal hyperplasia, the migration and proliferation
25 of medial smooth muscle cells, until the vessel is again occluded.

Stents are typically tubular metallic devices, which are thin-metal screen-like
scaffolds, and are inserted in a compressed form and then expanded at the target site. The
stents are intended to provide long-term support for the expanded vessel, to keep it from
restenosing over time. Unfortunately, initial data from the clinic indicates that the stent
30 implants are not entirely successful in their mission, and in as many as 30% or more of the
cases, the vessel restenoses within one year. It would be desirable to have medication(s)

When coronary stents are placed, patients often are subjected to aggressive anti-thrombogenic, anti-platelet regimes in order to prevent thrombus formation on the stent surfaces. Thrombus formation on stent surfaces can be a natural consequence of placement of metal objects in the vasculature. It is recognized that the thrombi formed on stents may break loose from the stent, and produce undesired and dangerous occlusions elsewhere in the vasculature. Unfortunately, an aggressive anti-thrombogenic regime compromises a patient's ability to heal injuries that accompany the stenting procedure or other collateral procedures that may have been required. Thus, it is desirable that methods be found that reduce the need for the aggressive anti-thrombogenic therapy associated with coronary stent placement.

To address these problems, various approaches have been proposed. In EP 0 706 376 B1, Burt, et al, proposed that paclitaxel could be incorporated in polymeric layers. Examples included polycaprolactam, poly (lactic-co-glycolic acid), and others. However, many of these layers are biodegradable, and may thus depend upon the enzymatic composition of the patient. It is known that the enzymatic compositions vary considerably from patient to patient. It is thus likely that the biodegradation process and drug release rate would occur at different rates from patient to patient. Furthermore, the polymers used in this disclosure possess inferior adhesion for this application.

US 5,837,008, Berg, et al., 5,851,217, Wolff, et al., and 6,344,035, Chudzik, et al., describe incorporation of drugs in multiple layers of a polymer on stents, wherein the drug-polymer layers are applied in one or more consecutive applications. Polymers listed include bioabsorbable and biostable examples. Bioabsorbable examples listed include poly (L-lactic acid), poly(lactide-co-glycolide), and poly(hydroxybutyrate-co-valerate). Drugs listed include heparin and other anticoagulant agents, glucocorticoid or other anti-inflammatory agents, and various anti-replicate agents. Bioabsorbable polymers may depend on the enzymatic composition of the patient, and may be subject to patient to patient variation in drug release. Also, such polymers possess inferior adhesion for this application. Biostable polymers listed include silicone, polyurethanes, polyesters, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers, and cellulotics. Furthermore, the use of a single polymer in the drug release layer limits the drug release dynamics to that enabled by the specific polymer used in the layer, and is thus less able to

WO 02/074194 PCT/US02/08039
regulate the drug release dynamics to the same extent as is possible using hybrid polymer layers. Further, optimizing drug release dynamics does not provide a coating with the necessary adhesion and flexibility to be clinically acceptable on a stent.

It has been proposed to provide stents, which are seeded with endothelial cells. In one experiment, sheep endothelial cells that had undergone retrovirus-mediated gene transfer for either bacterial beta-galactosidase or human tissue-type plasminogen activator were seeded onto stainless steel stents and grown until the stents were covered. The cells could therefore be delivered to the vascular wall where they could provide therapeutic proteins. Other methods of providing therapeutic substances to the vascular wall include simple heparin-coated metallic stents, whereby a heparin coating is ionically or covalently bonded to the stent.

U.S. Patent No. 5,843,172 to Yan, describes a porous metallic stent in which medication is loaded into the pores of the metal. The stent may also have a polymeric cover, which would contain a different drug than the drug that was loaded into the metal pores. This has the ability to deliver more than one drug, but the ability to mediate the drug release dynamics is limited by the fact that only one type of polymer is used, and the drug in the metallic pores is not bound in a polymeric medium. It has been found that the use of pores without polymer entrapment of the drug results in the drug release rate/profile being entirely dependent on the drug solubility.

Finally, Von Bergelen et al. "The JOSTENT™ Coronary Stent Graft-Just Another Stent?...or How Should it be Implanted?", Abstract: 825-4, ACC 2000/49th Annual Scientific Session, March 12-15, 2000, Anaheim, CA, USA, describes a sleeve of two stents with an ultra thin PTFE tube there between, which was implanted in 24 patients who had suffered acute coronary ruptures. This method mandates the use of oversized high-pressure balloon catheters to achieve adequate expansion of this new coronary stent graft (CSG). In addition, the endoprosthesis must be accurately sized and placed to avoid occlusion of side branches originating from the target lesion segment, and thrombus formation is a concern.

Thus, there is a need for technology that can consistently provide therapeutic activity from the surfaces of stents in order to reduce the incidence of restenosis and thrombus formation after coronary stenting procedures in the clinic.

SUMMARY OF THE INVENTION

In one embodiment, the present invention comprises a stent on which multiple polymer layers are applied to the stent surfaces, at least one (but not all) of which polymer layers provide reservoirs for a variety of individual drugs or drug cocktails. The polymer layers may be hybrid polymer layers, and may serve different purposes in the multi-layer stent coating.

The polymer layers of the invention typically comprise a bonding or primer layer, which can be applied directly onto the metallic stent surface. An intermediate polymer layer optionally can be applied over the primer layer. The intermediate polymer polymer layer is used to enhance the flexibility, elasticity, and expandability of the composite hybrid polymer layers. Next, one or more drug carrier polymer layers can be applied over the intermediate layer, or if an intermediate layer is not used, directly onto the primer layer. One or more of the polymer layers may be a hybrid polymer layer. As used herein, a hybrid polymer layer is one in which two or more different polymers are combined forming a layer, which is a homogeneous polymeric alloy. In the instant invention, a primer hybrid polymer contains polymers designed to provide anchorage to the stent surface. An intermediate hybrid polymer layer contains polymers capable of imparting enhanced flexibility and elasticity to the coating composite and adhesion to the primer and to the drug release layers. The drug release layer preferably is also a hybrid polymer layer, but contains different polymers from those used in the other two layers.

The polymer layers of the invention possess excellent flexibility and elasticity, and they are expandable, so as to remain intact following sterilization, implantation in the patient, and stent expansion. The polymer layers are not significantly bioerodable, so that differences in hormonal activity from patient to patient are minimized. The polymer layers can regulate drug release dynamics because hydrophilic and hydrophobic polymers are employed.

The drug-loaded layers of the invention provide technology for entrapping therapeutic drug mixtures in designed, biocompatible, hybrid polymer layers. In one embodiment of the invention, the polymer layers serve as reservoirs for the drugs, and protect and stabilize the drugs during sterilization and storage. The polymer layers can be porous to body fluids, such that the drugs can become solubilized via diffusion of body

fluids into the polymer layers, with subsequent diffusion of the solubilized drugs out of the layers at controlled rates. The polymer-drug layers can be deposited over the polymeric coated stent scaffolds, which can be deliverable to stenosed lesions via catheters, such as in the manner currently practiced in the clinic. The polymer layers are designed to provide efficacious drug concentrations for appropriate time periods at the stenosed site. For example, drug-polymer layers may provide fast drug release for about one to three days, followed by a slower sustained drug release rate for one week, two weeks, 30 days or longer, as needed. The sum of the periods of fast and slow release may be referred to as a sustained period. The drug release layers can also be designed to provide different drug release rate profiles, if desired, by for instance adjusting the ratio of hydrophilic to hydrophobic polymers in the polymer drug release layer.

In one embodiment of the invention, the polymer layers comprise polymeric alloys of polyvinylpyrrolidone, cellulose esters, and polyurethanes, acrylate polymers and copolymers, polyethylene glycols, polyethylene oxides, hydrophilic acrylate polymers and copolymers, melamines or epoxides in order to alter diffusion dynamics, or to enhance physical properties such as adhesion, flexibility, and abrasion resistance by varying the components in the casting solution (especially the ratio of hydrophilic to hydrophobic polymers). It is contemplated that for a faster drug release, a higher ratio of hydrophilic polymer to hydrophobic polymer would be used and visa versa to slow the drug release.

In another embodiment of the invention, the surface properties of the coating can be further influenced by its relative composition, having varying degrees for example, from highly lubricious to essentially non-lubricious. By including pharmacological agents in the surface layer, the surface can become a drug reservoir and provide high regional drug concentrations, while systemic concentrations remain low. Such polymeric alloys are described herein, and also in U.S. 5,069,899, Whitbourne, et al., titled "Anti-thrombogenic, anti-microbial compositions containing heparin;" U.S. 5,525,348, Whitbourne, et al., titled "Coating compositions comprising pharmaceutical agents;" U.S. 6,086,547, Hanssen, et al., titled "Wire for medical use coated with polyether sulphone and a copolymer;" and U.S. 6,110,483, Whitbourne, et al., titled "Adherent, flexible hydrogel and medicated coatings;" published PCT international application WO 01/15526 titled "Anti-infective covering for percutaneous and vascular access devices and coating method;" U.S.S.N. 09/442,891, filed 11/18/99, titled "Flexible sealed coil-like devices;" and U.S.S.N. 60/196,781, provisional

The coating composition can be used to coat a variety of stents. Non-limiting examples include: either self-expanding stents (such as the Wallstent variety), or balloon-expandable stents (as are available in a variety of styles, for instance, Gianturco-Roubin, Palmaz-Shatz, Wiktor, Strecker, Cordis, AVE Micro Stent, Boston Scientific Nir stent, and Guidant MULTI-LINK® coronary stent). The stents are typically prepared from materials such as stainless steel or tantalum, or nitinol. They have various mesh patterns having sharp edges, and are shorter or longer and have lower or higher diameters. The coatings of the invention are suitable for all such stents and others known to those of skill in the art or to be subsequently developed.

One embodiment of the invention relates to a medicated stent having a coating comprising: (a) a primer layer comprising a first composition of one or more polymers, and (b) a drug reservoir layer comprising a second composition of one or more polymers, the polymer composition of the drug reservoir layer being distinct from the polymer composition of the primer layer, and the drug reservoir layer further comprising one or more active agents, the coating remaining intact upon stent expansion and during a sustained period thereafter, and releasing efficacious amounts of the active agent at the site of stent expansion.

In another embodiment, the medicated stent can further comprise an intermediate layer between the primer layer and the drug release layer, comprising a polymer composition distinct from the polymer composition of the primer and drug reservoir layers. This medicated stent may further comprise one or more image enhancing material(s) in one of the layers, or in a separate layer(s), that is capable of enhancing visibility if the device under ultra sound, magnetic resonance imaging, X ray imaging, and/or other imaging modality.

The medicated stent may comprise different agents that are contained within the same and/or different layers. The primer layer and/or the drug reservoir layer may be a single layer or may comprise two or more layers. Moreover, the intermediate layer may comprise multiple layers. The medicated stent may comprise more than one active agent.

In yet another embodiment, the primer layer comprises one or more polymers selected from the group consisting of acrylate polymer/copolymer, acrylate carboxyl and/or hydroxyl copolymer, polyvinylpyrrolidone/vinylacetate copolymer

WO 02/074194 PCT/US02/08039
(PVP/VA), olefin acrylic acid copolymer, ethylene acrylic acid copolymer, epoxy polymer, polyethylene glycol, polyethylene oxide, polyvinylpyridine copolymers, polyamide polymers/copolymers polyimide polymers/copolymers, and/or polyether sulfones. The intermediate layer may comprise one or more polymers selected from the group consisting of acrylate polymer/copolymer, acrylate carboxyl and/or hydroxyl, PVP/VA, polyurethane, 5 silicone urethane polymer, polycarbonate urethane polymer, polyvinylbutyral, and/or epoxy polymers.

The primer and/or intermediate and/or drug reservoir layer may comprise one or more polymer selected from the group consisting of polyurethane, polycarbonate urethane 10 polymer, and silicone urethane polymer.

In a further embodiment, the medicated stent may comprise one or more polymers having a flexural modulus greater than 1000 psi and elongation at break greater than 200%. The medicated stent may have a drug reservoir layer comprising a polymer selected from acrylate polymer/copolymer, acrylate hydroxyl and/or carboxyl copolymer, polyvinyl 15 pyrrolidone (PVP), PVP/VA, cellulose ester, polyurethane, polycarbonate-urethane polymer, silicone-urethane polymer, epoxy polymer, polyethylene glycol and/or polyethylene oxide. The medicated stent may have a drug reservoir comprising one or more polyurethanes, cellulose nitrate, and/or one or more other cellulose ester polymer(s).

In a further embodiment, the medicated stent may have a drug reservoir layer 20 comprising one or more polymers selected from acrylate polymer/copolymer, acrylate polymer/copolymer containing carboxyl and/or hydroxyl groups, cellulose nitrate and/or other cellulose ester. The medicated stent may have an active agent comprising an anti-restenotic agent effective at a stented site. The total coating thickness may be between about 0.3 and about 30 microns. The medicated stent may also have a primer layer having a 25 thickness between about 0.1 and about 5 microns, and the drug reservoir layer having a thickness of between about 0.1 and about 10 microns. Moreover, the medicated stent may comprise an intermediate layer having a thickness between about 0.1 and about 15 microns.

In other embodiments of the invention, the active agent is selected from one or more of anti-thrombogenic agents, anti-inflammatory agents, antineoplastic agents, anti-proliferative agents, cytostatic agents, cytotoxic agents, antimicrobial agents, anti-restenotic 30 agents, anti-platelet agents, and anti-coagulant agents. The active agent may also be selected from one or more of anti-fibrin and fibrinolytic agents, anti-platelet agents, prostacyclins

WO 02/074194 PCT/US02/08039
(and analogues), glycoprotein IIb/IIIa agents, thromboxane inhibitors, anti-thrombin and anti-coagulant agents, anti-mitotic, antiproliferative and cytostatic agents, antiangiogenic and angiostatic agents, ACE inhibitors, growth factor antagonists, antioxidants, vitamins, calcium channel blockers, fish oil (omega 3-fatty acid), phosphodiesterase inhibitors, nitric acid donor, Somatostatin analogues, immunosuppressives and antiinflammatory agents, antimicrobials, radionuclides including alpha, beta and gamma emitting isotopes, COX-2 inhibitors, endothelial promoters, kinase inhibitors, epidermal growth factor kinase inhibitors, tyrosine kinase inhibitors, MAP kinase inhibitors, protein transferase inhibitors, alone or in combinations.

10 In a further embodiment, the active agent may be selected from one or more of plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic acid, aspirin, monoclonal antibodies, peptides, drugs (e.g. ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, forskolin, angiopeptin, argatroban, dextan, heparin, LMW heparin, Enoxaparin, Dalteparin, hirudin, 15 recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin, other coumarins, vincristine, vinblastine, paclitaxel and its analogues, methotrexate, cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid, corticosteroids, colchicine, nitroprusside, paclitaxel, angiostatin and endostatin; genetic materials, oligonucleotides, Cilazapril, Lisinopril, Captopril, VEGF, FGF, Probucol, 20 Tocopherol, nifedipine, dipyridamole, Molsidomine, angiopeptin, prednisolone, glucocorticoid, dexamethasone, rifamycin, Re-188, Re-186, I-125, Y-90 celecoxib, Vioxx, dipyridamole, theophylline, alone or in combinations.

In another embodiment, the medicated stent may have a primer layer comprising one or more of acrylate/carboxyl polymer, epoxy polymer, polyvinylpyrrolidone vinylacetate 25 copolymer (PVP/VA). The primer layer may also comprise one or more of ethylene acrylic acid copolymer (EAA), epoxy polymer, and polycarbonate urethane.

In yet a different embodiment of the invention, the intermediate layer may comprise polycarbonate polyurethane. The medicated stent may have a drug release layer comprising one or more of acrylate/carboxyl polymer, epoxy polymer, and polyvinylpyrrolidone 30 vinylacetate copolymer (PVP/VA). The drug release layer may comprise nitrocellulose. The drug release layer may also comprise nitrocellulose and one or more of polytetramethylene ether glycol urethane, polycarbonate-urethane, silicone-urethane

polymer, polyethylene glycol, polymethylmethacrylate-2-hydroxyethylmethacrylate copolymer, polyethylmethacrylate-2-hydroxyethylmethacrylate copolymer, polypropylmethacrylate-2-hydroxyethylmethacrylate copolymer, polybutylmethacrylate-2-hydroxyethylmethacrylate copolymer, polymethylacrylate-2-hydroxyethylmethacrylate copolymer, polyethylacrylate-2-hydroxyethylmethacrylate copolymer, polypropylacrylate-2-hydroxymethacrylate copolymer, polybutylacrylate-2-hydroxyethylmethacrylate copolymer, methylvinylether maleicanhydride copolymer, and poly (2-hydroxyethyl methacrylate). The active agent may be selected from the group consisting of paclitaxel, heparin complexes, rifamycin, and methotrexate.

10 Another aspect of the invention relates to a method for making a medicated stent having struts becoming separated upon stent expansion, comprising: applying a primer polymer liquid comprising one or more polymers in a volatile medium, applying a drug reservoir polymer liquid comprising one or more polymers in a volatile medium, the one or more drug reservoir polymers being different from the one or more primer layer polymers, 15 and applying an active agent either together with or after applying the drug reservoir polymer liquid, and removing the volatile media, the layers being applied without forming coating bridges between struts of the stent, the layers remaining intact upon stent expansion, and releasing efficacious amounts of the active agent at the site of stent expansion. Other embodiments may require more than one active agent to be applied or repeating one or more 20 of the applying steps. The invention may involve application of an intermediate flexibilizing polymer liquid comprising one or more polymers that differ from the one or more polymers of the primer layer and the drug reservoir layer. The volatile media may have a boiling point greater than about 110 degrees C. The liquids may have a viscosity between about 20 and about 70 cps.

25 In yet another aspect, the invention relates to a method for making a medicated stent comprising applying a primer polymer layer and a drug reservoir layer comprising at least two polymers and one or more active agent(s), wherein the polymer compositions of the primer and drug reservoir are different, without forming coating bridges between struts of the stent, the coating remaining intact upon stent expansion, and releasing efficacious 30 amounts of the active agent(s) at the site of stent expansion.

In a further aspect, the invention relates to a method for administering a bioactive agent to a target site in a subject, comprising: implanting a stent at the target site of the

subject, the stent comprising a coating having a primer layer and a drug release layer, the drug release layer comprising the bioactive agent, and the primer and drug release layers comprising different polymers, expanding the stent, and allowing the bioactive agent to elute from the coating during an extended period, the coating remaining intact during implanting, during stent expansion, and during the extended period.

The invention also relates to a medicated stent comprising: a stent body, a biologically active agent, means for containing and controllably releasing the agent from the stent over an extended period, comprising a first polymer, and means for bonding the containing means to the stent body, comprising a second polymer, the containing and bonding means remaining intact upon stent expansion and during the extended period.

The elements of the invention recited herein may be combined or eliminated among the particular embodiments described, as would be apparent to a person of ordinary skill.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1, which contains data from Table 1, Example 1 shows the cumulative quantity of paclitaxel eluted, in micrograms, over a period of 336 hours (14 days). Approximately 10% of the paclitaxel eluted out over a period of 14 days. The total amount of eluted drug and length of elution time are influenced by the amount of or the number of coatings of the drug releasing layer, the hydrophilicity of the layer(s), and the solubility of the drug(s) in the medium into which it/they are being released.

DETAILED DESCRIPTION OF THE INVENTION

In describing preferred embodiments of the present invention, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. It is to be understood that each specific element includes all technical equivalents, which operate in a similar manner to accomplish a similar purpose. The embodiments of the invention may be modified or varied, and elements added or omitted, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. Each reference cited here is incorporated by reference as if each were individually incorporated by reference.

In order to develop a hybrid polymer delivery system for targeted therapy, it is important to be able to control and manipulate the properties of the system both in terms of its physical and drug release characteristics. The active agents can be imbibed into a surface hybrid polymer layer, or incorporated directly into the hybrid polymer coating solutions.


5 Imbibing drugs into surface polymer layers is an efficient method for evaluating polymer-drug performance in the laboratory, but for commercial production it may be preferred for the polymer and drug to be premixed in the casting mixture. Greater efficacy can be achieved by combining the two elements in the coating mixtures in order to control the ratio of active agent to polymer in the coatings. Such ratios are important parameters to the final
10 properties of the medicated layers, *i.e.*, they allow for better control of active agent concentration and duration of pharmacological activity.

Typical polymers used in the drug-release system can include water-insoluble cellulose esters, various polyurethane polymers including hydrophilic and hydrophobic versions, hydrophilic polymers such as polyethylene glycol (PEG), polyethylene oxide
15 (PEO), polyvinylpyrrolidone (PVP), PVP copolymers such as vinyl acetate, hydroxyethyl methacrylate (HEMA) and copolymers such as methylmethacrylate (PMMA-HEMA), and other hydrophilic and hydrophobic acrylate polymers and copolymers containing functional groups such as carboxyl and/or hydroxyl.

Cellulose esters such as cellulose acetate, cellulose acetate propionate, cellulose
20 acetate butyrate, cellulose acetate phthalate, and cellulose nitrate may be used. The cellulose ester preferably serves as a polymer component in the hybrid polymer compositions. Cellulose nitrate is preferred because of its compatibility with the active agents and its ability to impart non-tackiness and cohesiveness to the coatings. Cellulose nitrate has been shown to stabilize entrapped drugs in ambient and processing conditions. Cellulose nitrate
25 (nitrogen content = 11.8-12.2%) preferably is used in this invention, although grades of the polymer having lower nitrate concentrations could be used. Viscosity grades, such as 3.5, 0.5 or 0.25 seconds, are used in order to provide proper rheological properties when combined with the coating solids used in these formulations. Higher or lower viscosity grades could be used. However, the higher viscosity grades can be more difficult to use
30 because of the high viscosities that obtain at the solids concentrations preferred in this invention. Lower viscosity grades, such as 3.5, 0.5 or 0.25 seconds, preferably are used in order to provide proper rheological properties when combined with the coating solids used

in these formulations. Physical properties such as tensile strength, elongation, flexibility, and softening point are related to viscosity (molecular weight) and can decrease with the lower molecular weight species, especially below the 0.25 second grades.


The cellulose derivatives comprise anhydroglucose structures. Cellulose nitrate is a hydrophobic, water-insoluble polymer, and has high water resistance properties. This structure leads to high compatibility with many active agents, accounting for the high degree of stabilization provided to drugs entrapped in cellulose nitrate. The structure of nitrocellulose is given below:




nitrocellulose

Cellulose nitrate is a hard, relatively inflexible polymer, and has limited adhesion to many polymers that are typically used to make medical devices. Also, control of drug elution dynamics is limited if only one polymer is used in the binding matrix, since the stent has significant variables such as coating thickness and the ratio of polymer to entrapped drug. In one embodiment, this invention uses polyurethane polymers with cellulose nitrate in the hybrid polymer drug loaded matrix. Polyurethanes provide the hybrid polymer matrix with greater flexibility and adhesion to the polymer coated stent surfaces of the invention. Polyurethanes can also be used to slow the drug elution from coatings. Aliphatic, aromatic, polytetramethylene ether glycol, and polycarbonate are among the polyurethanes, which can be used in the coatings.


From the structure below, it is possible to see how more or less hydrophilic polyurethane polymers may be created based on the number of hydrophilic groups contained in the polymer structures. The polyurethanes used in the invention are water-insoluble, flexible, and compatible with the cellulose esters.



Polyvinylpyrrolidone (PVP) is a polyamide that possesses unusual complexing and colloidal properties and is essentially physiologically inert. PVP and other hydrophilic polymers are typically biocompatible. PVP is incorporated in drug loaded hybrid polymer compositions in order to increase drug release rates. In one embodiment, the concentration of PVP that is used in drug loaded hybrid polymer compositions can be less than 20%. This concentration would not make the layers bioerodable or lubricious. In addition, PVP concentrations from <1% to greater than 80% are deemed workable.



Acrylate polymers and copolymers including polymethylmethacrylate (PMMA) and polymethylmethacrylate hydroxyethyl methacrylate (PMMA/HEMA) are known for their biocompatibility as a result of their widespread use in contact and intraocular lens applications. Some work describing the use of such copolymers in drug release coatings for stents has been reported in the literature. The coating was found to provoke very little smooth muscle and endothelial cell growth, and very low inflammatory response (Bar). These polymers/copolymers are compatible with drugs and the other polymers and layers of the instant invention.



Methylmethacrylate hydroxyethylmethacrylate copolymer.

The drug-loaded coatings can be prepared as coating solutions in organic solvents.

5 The solutions are non-reactive and can have a shelf life of up to 18 months when stored at room temperature. Among others, simple procedures (such as dipping or spraying, followed by air-drying) can be used to apply the hybrid polymer surfaces to stents. Drying the devices at elevated temperatures (40 to 120 °C) can remove the residual solvents to produce biocompatible surface layers of approximately 0.3 to 30 microns thick. Once dried, the
10 surface layers are stable for substantially the life of the sterile packaging, generally three to five years, depending on the drug(s) entrapped in the hybrid polymer layer, and on the storage conditions.

The polymers used in the primer layer may be cross-linkable and the coating may comprise a cross-linker for the polymers, such as epoxy resin, melamine resin, other amino
15 resin, and phenolic resins. The polymers may be selected from a carboxyl function acrylic polymer, hydroxyl function acrylic polymer, amine function acrylic polymer, methylol function, and amide function acrylic polymer. They may be a cross-linkable acrylic selected from methylmethacrylate, butylmethacrylate, isobutylmethacrylate, ethylmethacrylate, methylacrylate, ethylacrylate, butyl acrylate acrylic acid, methacrylic acid, styrene
20 methacrylate, and styrene acrylate, and copolymers thereof, and other non-acrylic polymers such as polyurethanes, polycarbonate-urethanes, silicone-urethanes, aliphatic polyurethanes, polyvinyl pyridine copolymers, polyethylene glycol, polyethylene oxide, polyamide copolymer, polyimide copolymer, other polymers known to those of skill in the art may be used in the primer layer.

25 The primer layer comprises hydrophobic polymers that are preferably water-insoluble polymers that do not significantly react with the hydrophilic polymers in solution, have low water absorption, provide a high degree of flexibility, and have improved bonding

to stent substrates. Suitable commercial products that may be used in the invention include acrylics such as ACRYLOID.RTM. (Rohm & Haas) AT-63, AT-51, AT-81, WR-97; ethylene acrylic acid copolymers such as PRIMACOR.TM. (DOW) 5989, 5990; melamine resins such as CYMELO.RTM. hexamethoxymethylmelamine (CYTEC Industries) 303, 370, 380; epoxies such as EPON (Shell) 1001; and polyvinylbutyral such as BUTVAR B-79 (Monsanto), polyurethanes such Tecoflex 93A, Chronoflex AR. The preferred acrylic stabilizing polymers include reactive groups such as hydroxyl or carboxyl that can react with epoxies but do not render the polymer hydrophilic.

In one embodiment, the inventive coating includes a hydrophilic polymer used in the primer and/or the drug reservoir layer(s), such as a water soluble polyolefin such as a hydrophilic vinyl polymer having polar pendant groups, a polyacrylate or methacrylate having hydrophilic esterifying groups, a polyether, a polyethylene glycol, or other polymer with hydrophilic characteristics as known in the art. The hydrophilic polymer is preferably PVP or PVP/vinyl acetate such as PVP/VA (GAF) E-335 and E-635.

The hydrophilic component may be of any of the classes discussed in Concise Encyclopedia of Polymer Science and Engineering, Kroschwitz, ed. (Wiley 1990), pp. 458-59, which is incorporated herein by reference. Polymers such as polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide, or polyvinyl alcohol are acceptable, alone or in combination. Examples of suitable hydrophilic polymers include homopolymers or copolymers of the following compounds: polyolefins such as vinyl polymers having polar pendant groups, N-vinylpyrrolidone, N-vinyl lactam, N-vinyl butyrolactam, N-vinyl caprolactam, sodium styrene sulfonate monomer, 2-acrylamido-2-methylpropane sulfonic acid, sodium vinyl sulfonate, vinyl pyridine, acrylates or methacrylates having hydrophilic esterifying groups. Other hydrophilic polymers include polyethers, polyethylene glycol, polysaccharides, hydrophilic polyurethanes, polyhydroxyacrylates, polymethacrylates, and copolymers of vinyl compounds and hydroxyacrylates or acrylic acid, so long as the appropriate hydrophilicity is present. Other examples include dextran, xanthan, hydroxypropyl cellulose, methyl cellulose, polyacrylamide, and polypeptides. Other hydrophilic components are known to persons of skill in the art.

The invention may require acrylics, e.g. polymers and copolymers of acrylic acid and methacrylic acid and esters thereof, as defined for example in ACRYLOID Thermoplastic Acrylic Ester Resins for Industrial Finishing, Rohm & Haas, Bulletin 82A37 (1987),

including cross-linkable acrylics with at least one component containing carboxyl, hydroxyl, amide, or methylol groups. The following ACRYLOID polymers with functional groups given are preferred: AT-51 (hydroxyl), AT-63 (hydroxyl), AT-81 (carboxyl), and WR-97 (hydroxyl). Cross-linkable acrylic emulsions such as RHOPLEX B-15J (Rohm & Haas), and styrene acrylic emulsions such as AROLON.RTM. 820-W-49 (Reichhold) may also be used.

A variety of polymers may be used, e.g., epoxy resins, particularly cured epoxy polymers such as EPOTUF.RTM. 38-505 (Reichhold), and preferably those cured with polyamide, such as EPOTUF.RTM. 37-618 (Reichhold), vinyl polymers, particularly vinyl acetate, vinyl acetals such as polyvinyl butyral, and ethylene vinyl acetate copolymers. Other appropriate polymers having the requisite characteristics will be apparent to persons of ordinary skill. The polymers preferably, but not necessarily, contain reactive groups or points of reactivity such as hydroxyls, mono-, di- and tertiary amines, acids such as carboxyl, amides, or other groups which represent points of chemical reactivity. In the case of the acrylics, this is referred to as having a "functionality" that is cross-linkable. The polymers and points of chemical reactivity are able to form attractive forces such as hydrogen bonding toward the medical device surface, and also toward the hydrophilic polymer and/or bioactive agent. Such bonds are very strong, and provide desirable adhesion and flexibility to the coating presumably without requiring covalent, ionic, or other links.

Polymers with reactive groups are preferred in the primer layer with stents, which present a metal substrate. However, polymers lacking such groups such as acrylic or styrene copolymers may also be used effectively. The reactive groups can also react to form a cross-linked matrix or help to form a cross-linked matrix. If desired, cross-linkers such as urea resins, melamines, isocyanates, phenolics, and others may be incorporated to interact with the points of chemical reactivity on the polymer chains to cross-link the polymers of the invention with themselves. Alternatively, cross-linkers may react with themselves as stabilizing polymers to form a cross-linked matrix in which the hydrophilic polymer is enmeshed, resulting in an adherent, flexible coating. Cross-linking is useful in promoting effective adhesion by ensuring that the solvents do not attack and degrade the polymer layer excessively when subsequent layers are applied.

The drug reservoir layer comprises mixtures of more and less hydrophilic polymers. Hydrophobic polymers comprise cellulose esters such as cellulose nitrate, polycarbonate-urethanes, acrylate polymers and copolymers with or without functional groups such as

those previously cited in this disclosure. Hydrophilic polymers comprise vinyl polymers with hydrophilic pendant groups such as PVP and its copolymers, polyethylene glycol, polyethylene oxide, HEMA, HEMA-acrylate and methacrylate copolymers, and other hydrophilic polymers/copolymers previously cited in this disclosure.

5 The coatings of the present invention are extremely durable, even when subjected to adhesion and flexing tests, as shown in the examples. Such enhanced adhesion and flexibility is a surprising result. The coatings according to the invention may be applied to the surface of a biomedical device or other device with sufficient thickness and permanence to retain the coating's desirable qualities throughout the useful life of the coated device. The
10 coatings of the invention are nonreactive with living tissue and are non-thrombogenic in blood. They are not substantially biodegradable.

 The coatings of the invention may be thin, on the order of 0.9 to 100 microns, preferably less than about 50 or 30 microns, and coherent in that they form a continuous surface layer on the stent as manufactured, and retain the coherence on the stent after
15 expansion. They are resistant to removal on prolonged soaking in aqueous fluids, and are adherent to a wide variety of substrates.

 The coatings may be applied by various techniques such as dip, pour, pump, spray, brush, wipe, or other methods known to those skilled in the art. The coating solutions have low viscosities, typically less than 100 CPS, and have good spreading properties. The
20 coatings are preferably baked at elevated temperatures, typically 50 degrees C to 140 degrees C, to drive off the organic solvents. It may be necessary to treat some surfaces like polyethylene with gas plasma or other ionizing treatment to promote interaction with the coating and adhesion to the substrates.

 The coating may contain polymers in addition to the stabilizing polymer such as
25 polyurethane, polyester, styrene polybutadiene, polyvinylidene chloride, polycarbonate, and polyvinyl chloride, preferably in the inner layer to promote adhesion to the surface of the device.

Anti-restenosis and other active agents

 Examples of active agents that be combined with the hybrid polymer carrier layers of
30 the invention include anti-fibrin and fibrinolytic agents, including plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic

acid; anti-platelet agents including, aspirin, prostacyclins (and analogues); glycoprotein IIb/IIIa agents including monoclonal antibodies, peptides (e.g. ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, forskolin, angiopeptin, argatroban), thromboxane inhibitors; anti-thrombin and anti-coagulant agents, including dextran, heparin, LMW heparin (Enoxaparin, Dalteparin), hirudin, recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin (and other coumarins); anti-mitotic, antiproliferative and cytostatic agents, including vincristine, vinblastine, paclitaxel, methotrexate, cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid, corticosteroids, colchicine, nitroprusside; antiangiogenic and angiostatic agents, including paclitaxel, angiostatin and endostatin; genetic materials and oligonucleotides; ACE inhibitors (e.g. Cilazapril, Lisinopril, Captopril); growth factor (e.g. VEGF, FGF) antagonists; antioxidants and vitamins (e.g. Probucol, Tocopherol); calcium channel blockers (e.g. nifedipine); fish oil (omega 3-fatty acid); phosphodiesterase inhibitors (e.g. dipyridamole); nitric acid donor (e.g. Molsidomine); somatostatin analogues (e.g. angiopeptin); immunosuppressives and anti-inflammatory agents (e.g. prednisolone, glucocorticoid and dexamethasone); antimicrobials (e.g. rifamycin) and radionuclides, including alpha, beta and gamma emitting isotopes (e.g. Re-188, Re-186, I-125, Y-90); COX-2 inhibitors such as Celecoxib and Vioxx; kinase inhibitors, such as epidermal growth factor kinase inhibitor, tyrosine kinase inhibitors, MAP kinase inhibitors protein transferase inhibitors, Resten-NG, and other biologically active agents and biologic response modifiers, and others, alone or in combinations to exert multiple actions simultaneously in order to prevent restenosis, and provide other desired biological effects.

The amount of active agent loaded in coatings which have been produced according to the invention has been in the range of about 25 to about 600 micrograms, although lower and higher loadings may be used depending on a variety of factors, including the drug, the desired dosage level, the drug release layer composition, the type of stent, the diameter and length of stent, the number of layers and how the active agent is applied, the coating thickness, the chemical characteristics of the active agent, and other factors. These factors are adjusted to provide a durable coating that controllably releases the desired amount of active agent over an extended period. In a typical desired release pattern, 25% of the active agent is released in the first few days, the remainder being released gradually over 30 or more days. Other release patterns may readily be achieved using the inventive methods and compositions, depending on the therapeutic effect desired (eg anti-angiogenesis, anti-cancer,

The hybrid polymer layers of the invention possess physical properties that enable their useful application on stents. For instance, the hybrid polymers of the invention achieve excellent adhesion on the metallic stent surfaces. The adhesion of the hybrid polymer layers of the invention is made possible by the use of certain bonding layers as described in U.S. Patent 5,997,517, incorporated herein by reference in its entirety.

Furthermore, the hybrid polymers of the invention, together with the multi-layer composite structure, ensure that the drug layers will remain well adhered to the stent surface, even during expansion of the stent, and will not lose their adhesion during prolonged implantation. The polymers of the invention do not alter the mechanical stent functions, such as forces required for expansion and strength so that the stent will resist collapsing after implantation.

In one embodiment of the invention, the production of stents can begin with the application of the bonding primer layer. In one embodiment, the primer layers can be on the order of about 0.1 to about 5 microns thick. Cross-linked primer layers can be thinner than non-cross-linked layers. The primer layer can be applied by dipping the stent in the primer coating solution, followed by drying at elevated temperatures in order to drive off the solvents in the coating solution, and to cure and cross-link the primer layer.

The primer layer may be subjected to turbulent airflow to open any bridging that occurs prior to the curing step. It is also possible to spray the primer coating onto the stent. Typical curing schedules include drying for fifteen to sixty minutes at 100°C to 120°C. The hybrid polymer primer layers comprise polymeric alloys that include such polymers and copolymers as acrylate polymers and copolymers, especially those having functional groups including amine, hydroxyl, and carboxyl, etc., epoxy resins, amine resins, ethylene acrylic acid copolymers, polyurethanes (especially more hydrophobic versions), copolymers of polyvinylpyrrolidone such as with vinyl acetate, polyether sulfones, and others.

The use of one or more intermediate layers is optional, although preferred. The intermediate layer can be applied over the primer layer using substantially the same methods as described for the primer layer, including similar curing schedules at elevated temperatures. The intermediate layer is employed to enhance the flexibility, elasticity, and expandability properties of the composite coating layers. It is recognized that thin layers in

a composite when constructed appropriately will acquire the properties of its components.

The intermediate layer is intended to contribute to and enhance the flexibility, elasticity, and expandability properties of the composite layers. An example of a polymer which performs well in this role is a polycarbonate-polyurethane having a flexural modulus (1% secant modulus (psi) (ASTM procedure D790)) greater than 1,000 or 3,000, and elongation at break greater than 200% or 300%. In a typical embodiment, the primer layer preferably would be about 0.1 to about 5 microns thick, and the intermediate layer would be about 0.1 to about 15 microns thick. This is because it is intended that the ultra flexible intermediate layer contributes substantially to the flexibility of the composite coating, and therefore preferably is at least as thick as the adjacent layers.

In practice, the invention employs polymers and copolymers which are useful in the intermediate layer and include vinyl acetals, especially polyvinyl butyral, polyurethanes which are more flexible and elastic and expandable, polycarbonate polyurethanes are especially useful for this purpose, acrylate polymers and copolymers which are elastic, flexible, and expandable. Other polymers and copolymers could also be used in this application, provided that they contribute the appropriate physical properties, are compatible and adherent to the adjacent layers, and are biocompatible.

The drug releasing hybrid polymer layer can comprise two or more polymers, together with one or more drugs, which can be dissolved in an organic solvent or solvent mixture. The drug(s) are usually dissolved in the organic solvent mixture, but may also be present as dispersions of solid particles. The hybrid polymer matrix forms a polymeric alloy upon drying. In the preferred embodiment, this layer can be typically about 1 to about 10 microns thick. The hybrid polymer matrix can be applied as one layer, or as two or more layers, and different drugs may be present in the same or different layer(s). When multiple layers are employed, the different layers could have the same or different drug release properties.

Soluble drugs can also form into the polymeric alloy at the molecular level. An organic solvent or solvent mixture can be selected so that it is a mutual solvent for the polymeric and soluble drug components, while in the liquid form, and throughout the drying process. It is also preferable if the solvent has the ability to swell the substrate, thereby enabling some of the drug-hybrid polymer components to penetrate superficially into the substrate surface and gain improved adhesion. The polymeric components of the drug

releasing layer can comprise cellulose esters to stabilize and preserve the drug components, and usually contain a relatively hydrophilic polyurethane. The polyurethane contributes flexibility, elasticity, and expandability to the drug-releasing layer. Other polymers may also be incorporated into the layer, including hydrophilic, water soluble polymers such as polyvinylpyrrolidone (PVP), PVP copolymers, polyethylene glycol, polyethylene oxide water soluble cellulose ethers and esters such as hydroxymethylcellulose, others. Drugs selected from the groups that were previously cited may be incorporated, alone or in combinations.

In one embodiment of the invention, the coating solutions are prepared by first dissolving the polymer components in the solvent mixtures. It is also possible to dissolve the individual polymer components separately in solutions, and then to combine together separate solutions of the individual polymers. The drug(s) are then usually incorporated into the hybrid polymer solution, although the drugs can be added before the polymers. The drug releasing coating is then applied over the stent, which already has one, or more polymer coatings, using the same methods as used for the other polymer coatings. After coating, the coating is dried for five to sixty minutes at temperatures of 40° C - 120° C.

The coated stents can be packaged and sterilized. Ethylene oxide is useful for sterilization of stents prepared according to the invention.

The following examples are intended to illustrate embodiments of the invention and are not intended to limit the scope of the invention. It should be understood that the concentrations of the components of the solutions of the examples may be varied within the scope of the invention and that the components may be used in different combinations, and with additional or different polymers as described above.

In coatings of the invention, the primer (bonding) layer uses a polymer combination of

(1) acrylate/carboxyl polymer + epoxy polymer + polyvinylpyrrolidone vinylacetate copolymer (PVP/VA) or

(2) ethylene acrylic acid copolymer (EAA) + epoxy polymer + polycarbonate urethane.

Other polymers may be used in this role, including polyimide copolymers, polyamide copolymers, polyether sulfone polymers, polyethylene glycol polymers, polyethylene oxide

polymers, other polymers which typically are used in metal primer applications.

An intermediate layer may be polycarbonate polyurethane, flexible acrylate polymers/copolymers including butyl acrylate, polyvinyl butyral, other elastic polymers used alone or in hybrid polymer combinations.

5 A drug release layer polymer combinations suitable for use with the invention are acrylate/carboxyl polymer + epoxy polymer + polyvinylpyrrolidone vinylacetate copolymer (PVP/VA), RS Nitrocellulose plus any of the following:

10 polytetramethylene ether glycol urethane, polycarbonate-urethanes, PVP, polyethylene glycol, polyethylene oxide, Methylvinylether maleicanhydride copolymer, and/or Poly(2-hydroxyethyl methacrylate).

Active ingredients used with these combination coatings include paclitaxel, benzalkonium heparinate, rifamycin, and methotrexate

15 These polymer combination and the ratios specified in the examples are not limiting, and other suitable combinations and ratios may be used as long as they provide the desired adhesion and drug release effects of the invention.

In the following examples: Polyurethane 1 is a polycarbonate urethane; Polyurethanes 2 and 3 are polytetramethylene ether glycol urethanes; Cellulose Ester 1 is RS Nitrocellulose, 1/4 sec grade; Cellulose Ester 2 is RS Nitrocellulose, 5-6 sec grade. The terms nitrocellulose and cellulose nitrate are also used for these latter compounds.

20

EXAMPLE 1

The following solutions were prepared:

Composition 1

| | |
|--|----------|
| Acrylate/carboxyl polymer, 55.5 % solution (1) | 8.33 gm |
| Tetrahydrofuran (THF) | 39.58 gm |
| Cyclohexanone | 41.60 gm |
| PVP/VA Polymer Solution (2) | 2.73 gm |
| Ethanol | 1.37 gm |

Composition 2

| | |
|---|----------|
| Epoxy Polymer Solution (3) | 2.56 gm |
| PVP/VA Polymer Solution (2) | 2.79 gm |
| Acrylate/carboxyl polymer, 55.5% Solution (1) | 8.50 gm |
| Cyclohexanone | 42.70 gm |
| THF | 36.70 gm |
| Ethanol | 5.56 gm |
| Paclitaxel | 1.00 gm |

5 (1) This copolymer solution is 55.5% (w/w) solids in aromatic 150/butyl cellosolve, 87.5/12.5.

(2) This copolymer solution is 50.0% (w/w) solids in ethanol.

(3) This epoxy polymer is 75% (w/w) solids in xylene

10 Composition 1 was coated on stainless steel coronary stents, and dried for 60 minutes at 120°C. This layer was applied twice. Composition 2 was then coated over the primer layers, and dried for 60 minutes at 120°C. Drug loading on the stents in the range of 50-60 µg was achieved by applying composition 2 three times and drying after each application. The stent samples with three layers of composition 2 were subjected to elution in room
15 temperature phosphate buffered saline for times up to 336 hours, and produced the following results tabulated in TABLE 1.

| Sample Identification and Elution Time | Analysis #1 Paclitaxel Conc. ($\mu\text{g/ml}$) | Analysis #2 Paclitaxel Conc. ($\mu\text{g/ml}$) | Average Paclitaxel in Eluent ($\mu\text{g/ml}$) | Extract volume (ml) |
|--|---|---|---|---|
| Sample 1, 2 hr. | 0.6 | 0.7 | 0.65 | 1.5 |
| Sample 1, 4 hr. | 0.5 | 0.5 | 0.50 | 1.5 |
| Sample 1, 6 hr. | 0.4 | 0.4 | 0.40 | 1.5 |
| Sample 1, 8 hr. | 0.3 | 0.4 | 0.35 | 1.5 |
| Sample 1, 24 hr. | 0.3 | 0.3 | 0.30 | 1.5 |
| Sample 1, 48 hr. | 0.3 | 0.3 | 0.30 | 1.5 |
| Sample 1, 168 hr. | 0.4 | 0.4 | 0.40 | 1.5 |
| Sample 1, 216 hr. | 0.3 | 0.3 | 0.30 | 1.5 |
| Sample 1, 336 hr. | 0.3 | 0.3 | 0.30 | 1.5 |
| Sample Identification and Elution Time | μg Paclitaxel Released | % of Total Paclitaxel released over 336 hours | Elution Time Cumulative Hrs. | Paclitaxel Release Cumulative μg |
| Sample 1, 2 hr. | 0.98 | 18.6 | 2 | 0.98 |
| Sample 1, 4 hr. | 0.75 | 14.3 | 4 | 1.73 |
| Sample 1, 6 hr. | 0.60 | 11.4 | 6 | 2.33 |
| Sample 1, 8 hr. | 0.53 | 10.0 | 8 | 2.85 |
| Sample 1, 8 hr. | 0.53 | 10.0 | 8 | 2.85 |
| Sample 1, 24 hr. | 0.45 | 8.6 | 24 | 3.30 |
| Sample 1, 48 hr. | 0.45 | 8.6 | 48 | 3.75 |
| Sample 1, 168 hr. | 0.60 | 11.4 | 168 | 4.35 |
| Sample 1, 216 hr. | 0.45 | 8.6 | 216 | 4.80 |
| Sample 1, 336 hr. | 0.45 | 8.6 | 336 | 5.25 |

The data show that approximately 10% of the paclitaxel eluted out over a period of 14 days. The data plotted in Figure 1 show the cumulative quantity of paclitaxel eluted, in micrograms, over a period of 336 hours (14 days). While not wishing to be bound thereby, it is believed that the rate of drug elution is independent of the number of coated layers, and that the total amount of eluted drug and length of elution time are influenced by the amount of or the number of coatings of the drug releasing layer, the hydrophilicity of the layer(s), and the solubility of the drug(s) in the medium into which it/they are being released.

EXAMPLE 2

This example provides a composite coating of three flexible polymer or hybrid polymer layers. The hybrid polymer bonding layer solution was applied and dried at 120°C for 60 minutes. An intermediate layer was applied and dried at 120°C for 60 minutes. The drug release hybrid polymer layer was applied and dried at 75°C for 60 minutes. A high boiling point solvent was included in each formulation to aid in processing. Drug(s) can be imbibed into the drug release hybrid polymer layer, but the preferred method is to add the active agents to the coating liquid so that the drug/polymer layer can be controlled.

(All values are wt/wt %, unless otherwise specified)

Bonding layer

| | |
|---------------------------|---------|
| Polyurethane 1 | 0.78 % |
| EAA | 3.05 % |
| Epoxy | 0.90 % |
| Dimethyl acetamide (DMAC) | 2.67 % |
| Cyclohexanone | 33.66 % |
| THF | 58.94 % |

Intermediate layer

| | |
|----------------|---------|
| Polyurethane 1 | 8.80 % |
| DMAC | 66.20 % |

25.00 %

Drug release hybrid polymer layer

| | |
|-------------------|---------|
| Polyurethane 2 | 6.07 % |
| Cellulose ester 1 | 2.43 % |
| THF | 54.64 % |
| Ethanol | 21.85 % |
| DMSO | 15.01 % |

Stent samples coated with this example had good uniformity based on dye testing.

- 5 Coated stents that were expanded proved quite flexible and demonstrated excellent adhesion to the substrate.

EXAMPLE 3

10 This example considers a composite coating of three flexible polymer or hybrid polymer layers. A hybrid polymer bonding layer solution was applied and dried at 120°C for 60 minutes. An intermediate layer was applied and dried at 120°C for 60 minutes. A drug release hybrid polymer layer, as outlined below, was applied and dried at 75°C for 60 minutes. The drug release hybrid polymer layer contains one additional, ultra hydrophilic component that was not included in Example 2. It was expected that Example 3 would elute
15 more rapidly relative to Example 2. A high boiling solvent was included in each formulation to aid in processing. This drug release hybrid polymer layer is more susceptible to having the drug imbibed into it from solution than the drug release layer in Example 2. The preferred method is to add the active agents to the coating liquid to achieve better control of the drug/polymer ratio.

20 Bonding layer - Same as Example 2

Intermediate layer - Same as Example 2

Drug release hybrid polymer layer

| | |
|-------------------|-------|
| Polyurethane 2 | 5.05 |
| Polyurethane 3 | 2.17 |
| Cellulose ester 2 | 1.28 |
| THF | 46.75 |
| Ethanol | 29.75 |
| DMSO | 15.00 |

Stent samples coated with this example had good uniformity based on dye testing. Coated stents that were expanded demonstrated good flexibility and adhesion to the substrate, and did not crack.

5

EXAMPLE 4

This example considers a composite coating of 3 flexible polymer or hybrid polymer layers. A bonding layer solution was applied and dried at 120°C for 60 minutes. An intermediate layer was applied and dried at 120°C for 60 minutes. A drug release hybrid
10 polymer layer was applied and dried at 75°C for 60 minutes. (Example 3 is desirable as compared to Example 5 due to high boiling solvents (e.g., a boiling point over about 110° C) for processing, and lower viscosity solutions (e.g., about 20-70 cps), which are desired ranges for coating liquids.

Bonding layer

| | |
|----------------|-------|
| Polyurethane 1 | 0.80 |
| EAA | 3.90 |
| Epoxy | 1.15 |
| DMAC | 3.40 |
| Cyclohexanone | 15.60 |
| THF | 75.15 |

15

Intermediate layer

| | |
|----------------|------|
| Polyurethane 1 | 11.7 |
| DMAC | 88.3 |

Drug release hybrid polymer layer

| | |
|-------------------|-------|
| Polyurethane 2 | 7.14 |
| Cellulose ester 1 | 2.86 |
| THF | 64.29 |
| Ethanol | 25.71 |

5

The embodiment of Example 3 is preferred over that of Example 4 since high boiling solvents were incorporated in the drug release hybrid polymer layer in that example, which improves processing, makes it easier to prevent the coating from bridging between the struts of the stent, and provides lower solution viscosity.

10

EXAMPLE 5

This example concerns a composite coating of two flexible polymer or hybrid polymer layers. No bonding layer was applied. Solution was applied and dried at 120°C for 60 minutes. Drug release hybrid polymer layer was applied and dried at 75°C for 60 minutes.

15

Intermediate layer

| | |
|----------------|------|
| Polyurethane 1 | 11.7 |
| DMAC | 88.3 |

Drug release hybrid polymer layer

| | |
|----------------|------|
| Polyurethane 2 | 7.14 |
|----------------|------|

| | |
|---------|-------|
| | 2.86 |
| THF | 64.29 |
| Ethanol | 25.71 |

Example 3 is preferred over this example 5 due to improved composite integrity credited to the adhesion imparted by the bonding layer. Specifically, the composite of Example 3 showed strong adhesion to the substrate when abraded by rubbing with a finger
5 when immersed in water at room temperature. The composite coating of this example showed some breakdown/delamination when wet rubbed during water immersion.

EXAMPLE 6

In this example, two drugs (paclitaxel and benzalkonium heparinate) were combined
10 together in the drug release layer and were coated on a stainless steel stent. The bonding layer was applied by dip coating, and excess coating was blown off with nitrogen, and dried for 30 minutes at 100°C. The intermediate layer was applied by dip coating, and excess coating was blown off with nitrogen, and dried for 30 minutes at 100°C. The drug release layer was applied by dip coating, excess coating was blown off with nitrogen, and was dried
15 for 60 minutes at 75°C.

Bonding layer

| | |
|----------------|--------|
| Polyurethane 1 | 0.79% |
| EAA | 3.06% |
| Epoxy | 0.90% |
| Cyclohexanone | 33.64% |
| DMAC | 2.67% |
| THF | 58.94% |

Intermediate layer

DMAC

66.20%

Cyclohexanone

25.00%

Drug release layer

Polyurethane 2

5.89%

Nitrocellulose 2

2.36%

THF

53.00%

Ethanol

21.19%

DMSO

14.56%

Paclitaxel

1.00%

Benzalkonium heparinate

2.00%

5 This example showed good coating uniformity, good wet abrasion resistance, and good adhesion to the metal stent surface.

EXAMPLE 7

10 This example is similar to Example 6, except that the drug release layer contained only benzalkonium heparinate. The coatings were applied on a stainless steel stent using the same procedures as in Example 6.

Bonding layer - same as previous examples

Intermediate layer - same as previous examples

Drug releasing layer

Polyurethane 2

5.89%

Nitrocellulose 2

2.36%

THF

53.00%

21.19%

DMSO

14.56%

Benzalkonium heparinate

3.0%

This example also showed good coating uniformity, good wet abrasion resistance, and good adhesion to the metal stent surface.

5 EXAMPLE 8

This example is similar to Example 6, except that the drug release layer contained rifamycin. The coatings were applied on a stainless steel stent using the same procedures as in Example 6.

10 Bonding layer - same as previous examples

Intermediate layer - same as previous examples

Drug release layer

Polyurethane 2 5.89%

Nitrocellulose 2 2.36%

THF 53.00%

Ethanol 21.19%

DMSO 14.56%

Rifamycin 3.00%

EXAMPLE 9

15 In this example methotrexate was imbibed into the drug releasing layer from an aqueous solution. The bonding layer and intermediate layer are the same as were used in Example 6, and were applied using the same procedures.

Bonding layer - same as above

Drug release layer

| | |
|------------------|--------|
| Polyurethane 2 | 6.07% |
| Nitrocellulose 2 | 2.43% |
| THF | 54.64% |
| Ethanol | 21.85% |
| DMSO | 15.01% |

5 The drug release layer was applied and treated as in Example 8. After the oven curing process, the stent was cooled to room temperature, and then briefly immersed in an aqueous solution of methotrexate, 25mg/ml., and air dried. The coating absorbed drug from the aqueous solution.

EXAMPLE 10

10 Stents were coated with the following primer (BOND-COAT®, STS Biopolymers, Inc.) layer and intermediate layer, and dried 15 minutes at 100 ° C, after each application.

BOND-COAT® Primer Layer

| | |
|---------------------------------|--------|
| Polycarbonate polyurethane | 0.78% |
| Ethylene acrylic acid copolymer | 3.05% |
| Epoxy resin | 0.90% |
| DMAC | 2.67% |
| Cyclohexanone | 33.66% |
| THF | 58.94% |

Intermediate layer

| | |
|----------------------------|-------|
| Polycarbonate polyurethane | 1.28% |
|----------------------------|-------|

Cyclohexanone

27.05%

Next, the stent was coated with the following drug reservoir layer, and dried for 15 minutes at 75°C.

Drug Reservoir Layer

| | |
|----------------------------|---------|
| Polycarbonate polyurethane | 2.5 gm |
| Cellulose nitrate | 1.0 gm |
| Methyl ethyl ketone | 30.0 gm |
| n-Butanol | 20.0 gm |
| Dimethylacetamide | 41.4 gm |
| Cyclohexanone | 27.6 gm |
| Paclitaxel | 2.0 gm |
| Silicone polyurethane | 2.5 gm |

5

This solution coated uniformly, and resulted in a smooth, clear layer.

EXAMPLE 11

A coronary stent was coated with the primer and intermediate layers as in Example 10. Next, the stent was coated with the following drug reservoir layer, and dried using the same schedule as in Example 10.

Drug Reservoir Layer

| | |
|--------------------------|---------|
| Cyclohexanone | 6.29 gm |
| Dimethylacetamide | 4.31 gm |
| n-Butanol | 4.40 gm |
| Polyethylene glycol 3350 | 0.37 gm |

Paclitaxel

0.015 gm

This solution coated uniformly, and resulted in a smooth, clear layer.

EXAMPLE 12

- 5 A coronary stent was coated with the primer and intermediate layers as in Example 10. Next, the stent was coated with the following drug reservoir layer, and dried using the same schedule as in Example 10.

Drug Reservoir Layer

| | |
|---|----------|
| Tetrahydrofuran | 7.0 gm |
| Dimethylacetamide | 4.0 gm |
| Cyclohexanone | 6.0 gm |
| Methylvinylether maleic anhydride copolymer | 0.37 gm |
| Cellulose nitrate | 0.03 gm |
| Paclitaxel | 0.015 gm |

- 10 This solution exhibited solvent attack on the intermediate layer during coating.

EXAMPLE 13

- 15 A coronary stent was coated with the primer and intermediate layers as in Example 10. Next, the stent was coated with the following drug reservoir layer, and dried using the same schedule as in Example 10.

Drug Reservoir Layer

| | |
|-------------------|--------|
| Dimethylacetamide | 8.0 gm |
| Benzyl alcohol | 8.0 gm |

Paclitaxel

0.019 gm

This solution coated uniformly, and resulted in a smooth, clear layer.

EXAMPLE 14

- 5 A coronary stent was coated with the primer and intermediate layers as in Example 10. Next, the stent was coated with the following drug reservoir layer, and dried using the same schedule as in Example 10.

Drug Reservoir Layer

| | |
|----------------------------|---------|
| Polycarbonate polyurethane | 2.5 gm |
| Cellulose nitrate | 1.0 gm |
| Methyl ethyl ketone | 30.0 gm |
| n-Butanol | 20.0 gm |
| Dimethylacetamide | 18.9 gm |
| Cyclohexanone | 27.6 gm |
| Paclitaxel | 2.0 gm |

- 10 This solution coated uniformly, and resulted in a smooth, clear layer.

- Stents were expanded and inspected for cracking and adhesion failure. No cracking or chipping off was observed after stent expansion. Several coated stents were incubated in 37°C phosphate buffered saline (PBS) for various times up to 10 days. Stents were removed from the serum at their designated time points, and soaked in acetonitrile to remove the coating. The acetonitrile extract was tested via HPLC to determine how much paclitaxel remained on each stent after its incubation period. 60.4 % of the starting Paclitaxel remained on stents after 10 days of incubation on PBS.
- 15

This comparative example evaluates adhesion of gelatin and human albumin on metal stents.

Experiment

- 5 Stainless steel stents were coated with two biodegradable polymer solutions, 5% gelatin and 5% human albumin and tested for adhesion.

Materials

Commercial 15mm stainless steel stents

VEE GEE 150 Bloom Type A Economix Gelatin, Vyse Gelatin Company

- 10 5% human albumin solution, Alpha Therapeutic Corporation

1,1,1 trichloroethane, EM Science

stainless steel tabs, 1 cm x 8 cm

Triton X-100 nonionic surfactant, Ruger Chemical Company

Protocol

- 15 Prepare a 5% w/w solution of the gelatin by dissolving 5g of gelatin in 95g of filtered deionized water. Add 0.4% w/w Triton X-100 by mixing 0.1g of Triton X-100 to 24.9g of 5% w/w gelatin solution.

Human albumin comes as a 5% w/v solution. Add 0.4% w/w Triton X-100 by mixing 0.1g of Triton X-100 to 24.9g of 5% w/v human albumin solution.

- 20 Clean the steel tabs with 1,1,1 trichloroethane then coat with each of the polymer solutions by dip coat methods. Use a 5-second dwell time and approximately 3 cm/s draw speed. Allow samples to air-dry for ½ hour at room temperature then oven dry for one hour at 45° C. Test adhesion using the so-called tape test method, in which a strip of Scotch 810 Tape is firmly pressed onto the coated surface, and then pulled off abruptly. The coated
25 article and the tape are inspected to see if any of the coating was stripped off of the coated surface. No coating should be removed by this test. This test method has been widely accepted for many years by members of the coating industry as a useful predictor of coated product performance in use.

Repeat steel tab procedure using the 15mm stainless steel stents, except add one step.

After drawing the sample from the coating solution use helium to blow any excess polymer off the stent. (Remove any polymer that may be filling the holes in the stent.)

Results/Summary

5 The coating solutions both produce a uniform coating on the steel tabs. However, the tape dry adhesion tests show that both coatings failed. No other tests were preformed since they failed in the first test.

10 The coated stents were dyed with a Gentian Violet solution and compared to a dyed uncoated stent. The stent pieces were dipped into the solution and blotted dry with a paper towel. Both the coated stents showed a bright purple color while the uncoated stent did not show the bright purple color. This shows that the stents were covered with the polymer coatings. The samples underwent the dry adhesion tape test and were observed under a microscope. Polymer strands were seen to be coming off, showing the samples failed the adhesion test. No other tests were performed since they failed the first test.

Conclusion

15 The gelatin and human albumin polymers produce coatings that fail to adhere to steel tabs or stainless steel stents. The inventive coatings were far superior.

1. A medicated stent having a coating comprising:
 - (a) a primer layer comprising a first composition of one or more polymers, and
 - 5 (b) a drug reservoir layer comprising a second composition of one or more polymers, the first composition being distinct from the second composition, and the drug reservoir layer further comprising one or more active agents,the coating remaining intact upon stent expansion and during a sustained period thereafter, and releasing efficacious amounts of the active agent at the site of stent
10 expansion.
2. The medicated stent of claim 1 further comprising an intermediate layer between the primer layer and the drug release layer, comprising a polymer composition distinct from the first and second compositions.
15
3. The medicated stent of claim 1 or 2 further comprising one or more image enhancing material(s) in one of the layers, or in a separate layer(s), that is capable of enhancing visibility in ultra sound, magnetic resonance imaging, or X ray imaging.
- 20 4. The medicated stent of claim 1 or 2 wherein different agents are contained within the same and/or different layers.
5. The medicated stent of claim 1 or 2 wherein the primer layer and/or the drug reservoir layer is a single layer.
25
6. The medicated stent of claim 1 or 2 wherein the primer layer and/or the drug reservoir layer comprise two or more layers.
7. The medicated stent of claim 2 wherein the intermediate layer comprises
30 multiple layers.
8. The medicated stent of claim 1 or 2 comprising more than one active agent.

9. The medicated stent of claim 1 or 2 in which the primer layer comprises one or more polymers selected from the group consisting of acrylate polymer/copolymer, acrylate carboxyl and/or hydroxyl copolymer, polyvinylpyrrolidone/vinylacetate copolymer (PVP/VA), olefin acrylic acid copolymer, ethylene acrylic acid copolymer, epoxy polymer, polyethylene glycol, polyethylene oxide, polyvinylpyridine copolymers, polyamide polymers/copolymers polyimide polymers/copolymers, and/or polyether sulfones.

10. The medicated stent of claim 2 wherein the intermediate layer comprises one or more polymers selected from the group consisting of acrylate polymer/copolymer, acrylate carboxyl and/or hydroxyl, PVP/VA, polyurethane, silicone urethane polymer, polycarbonate urethane polymer, polyvinylbutyral, and/or epoxy polymers.

11. The medicated stent of claim 1 or 2 wherein the primer and/or intermediate and/or drug reservoir layer comprises one or more polymer selected from the group consisting of polyurethane, polycarbonate urethane polymer, and silicone urethane polymer.

12. The medicated stent of claim 1 or 2 comprising one or more polymers having a flexural modulus greater than 1000 psi and elongation at break greater than 200%.

13. The medicated stent of claim 1 or 2 having a drug reservoir layer comprising a polymer selected from acrylate polymer/copolymer, acrylate hydroxyl and/or carboxyl copolymer, polyvinyl pyrrolidone (PVP), PVP/VA, cellulose ester, polyurethane, polycarbonate-urethane polymer, silicone-urethane polymer, epoxy polymer, polyethylene glycol and/or polyethylene oxide.

14. The medicated stent of claim 1 or 2 having a drug reservoir comprising one or more polyurethanes, cellulose nitrate, and/or one or more other cellulose ester polymer(s).

15. The medicated stent of claim 1 or 2 having a drug reservoir layer comprising one or more polymers selected from acrylate polymer/copolymer, acrylate polymer/copolymer containing carboxyl and/or hydroxyl groups, cellulose nitrate and/or other cellulose ester.

16. The medicated stent of claim 1 or 2 wherein the active agent comprises an anti-restenotic agent effective at a stented site.

17. The medicated stent of claim 1 or 2 having a total coating thickness between about 0.3 and about 30 microns.

18. The medicated stent of claim 1 or 2, the primer layer having a thickness between about 0.1 and about 5 microns, and the drug reservoir layer having a thickness of between about 0.1 and about 10 microns.

19. The medicated stent of claim 2, the intermediate layer having a thickness between about 0.1 and about 15 microns.

20. The medicated stent of claim 1 or 2 wherein the active agent is selected from one or more of anti-thrombogenic agents, anti-inflammatory agents, antineoplastic agents, anti-proliferative agents, cytostatic agents, cytotoxic agents, antimicrobial agents, anti-restenotic agents, anti-platelet agents, and anti-coagulant agents.

21. The medicated stent of claim 1 or 2 wherein the active agent is selected from one or more of anti-fibrin and fibrinolytic agents, anti-platelet agents, prostacyclins (and analogues), glycoprotein IIb/IIIa agents, thromboxane inhibitors, anti-thrombin and anti-coagulant agents, anti-mitotic, antiproliferative and cytostatic agents, antiangiogenic and angiostatic agents, ACE inhibitors, growth factor antagonists, antioxidants, vitamins, calcium channel blockers, fish oil (omega 3-fatty acid), phosphodiesterase inhibitors, nitric acid donor, Somatostatin analogues, immunosuppressives and antiinflammatory agents, antimicrobials, radionuclides including alpha, beta and gamma emitting isotopes, COX-2 inhibitors, endothelial promoters, kinase inhibitors, epidermal growth factor kinase inhibitors, tyrosine kinase inhibitors, MAP kinase inhibitors, and protein transferase inhibitors.

22. The medicated stent of claim 1 or 2 wherein the active agent is selected from one or more of plasmin, streptokinase, single chain urokinase, urokinase, t-PA (tissue type plasminogen activator), aminocaproic acid, aspirin, monoclonal antibodies, peptides,

WO 02/074194 PCT/US02/08039
ReoPro, Cilastagel, eptifibatide, tirofiban, ticlopidine, Vapiprost, dipyridamole, torskolin,
angiopeptin, argatroban, dextran, heparin, LMW heparin, Enoxaparin, Dalteparin, hirudin,
recombinant hirudin, anti-thrombin, synthetic antithrombins, thrombin inhibitors, Warfarin,
other coumarins, vincristine, vinblastine, paclitaxel and its analogues, methotrexate,
5 cisplatin, fluorouracil, rapamycin, azathioprine, cyclophosphamide, mycophenolic acid,
corticosteroids, colchicine, nitroprusside, paclitaxel, angiostatin and endostatin; genetic
materials, oligonucleotides, Cilazapril, Lisinopril, Captopril, VEGF, FGF, Probucol,
Tocopherol, nifedipine, dipyridamole, Molsidomine, angiopeptin, prednisolone,
glucocorticoid, dexamethasone, rifamycin, Re-188, Re-186, I-125, Y-90 celecoxib, Vioxx,
10 dipyridamole, and theophylline.

23. The medicated stent of claim 1 or 2 wherein the primer layer comprises one
or more of acrylate/carboxyl polymer, epoxy polymer, polyvinylpyrrolidone vinylacetate
copolymer (PVP/VA).

24. The medicated stent of claim 1 or 2 wherein the primer layer comprises one
or more of ethylene acrylic acid copolymer (EAA), epoxy polymer, and polycarbonate
urethane.

25. The medicated stent of claim 1 or 2 wherein the intermediate layer comprises
polycarbonate polyurethane.

26. The medicated stent of claim 1 or 2 wherein the drug release layer comprises
one or more of acrylate/carboxyl polymer, epoxy polymer, and polyvinylpyrrolidone
25 vinylacetate copolymer (PVP/VA).

27. The medicated stent of claim 1 or 2 wherein the drug release layer comprises
nitrocellulose.

28. The medicated stent of claim 1 or 2 wherein the drug release layer comprises
nitrocellulose and one or more of polytetramethylene ether glycol urethane, polycarbonate-
urethane, silicone-urethane polymer, polyethylene glycol, polymethylmethacrylate-2-
hydroxyethylmethacrylate copolymer, polyethylmethacrylate-2-hydroxyethylmethacrylate

polybutylmethacrylate-2-hydroxyethylmethacrylate copolymer, Polymethylacrylate-2-hydroxyethylmethacrylate copolymer, polyethylacrylate-2-hydroxyethylmethacrylate copolymer, polypropylacrylate-2-hydroxymethacrylate copolymer, polybutylacrylate-2-hydroxyethylmethacrylate copolymer, copolymermethylvinylether maleicanhydride copolymer, and poly (2-hydroxyethyl methacrylate).

29. The medicated stent of claim 1 or 2 wherein the active agent is selected from the group consisting of paclitaxel, heparin complexes, rifamycin, and methotrexate.

30. A method for making a medicated stent comprising:

applying a primer polymer liquid comprising one or more polymers in a volatile medium,

applying a drug reservoir polymer liquid comprising one or more polymers in a volatile medium, the one or more drug reservoir polymers being different from the one or more primer layer polymers, and

applying an active agent either together with or after applying the drug reservoir polymer liquid, and

removing the volatile media,

the layers being applied without forming coating bridges between struts of the stent, the layers remaining intact upon stent insertion and expansion at a therapeutic site of a subject, and releasing efficacious amounts of the active agent at the therapeutic site.

31. The method of claim 30, comprising applying more than one active agent.

32. The method of claim 30, comprising repeating one or more of the applying steps.

33. The method of claim 30, further comprising applying an intermediate flexibilizing polymer liquid comprising one or more polymers that differ from the one or more polymers of the primer layer and the drug reservoir layer.

34. The method of claim 30, wherein the volatile media have a boiling point greater than about 110 degrees C.

35. The method of claim 30, wherein the liquids have a viscosity between about 20 and about 70 cps.

36. A method for making a medicated stent comprising applying a primer polymer layer and a drug reservoir layer comprising at least two polymers and one or more active agent(s), wherein the polymer compositions of the primer and drug reservoir are different, without forming coating bridges between struts of the stent, the coating remaining intact upon stent expansion, and releasing efficacious amounts of the active agent(s).

37. A method for administering a bioactive agent to a target site in a subject, comprising:

implanting a stent at the target site of the subject, the stent comprising a coating having a primer layer and a drug release layer, the drug release layer comprising the bioactive agent, and the primer and drug release layers comprising different polymers,

expanding the stent, and

allowing the bioactive agent to elute from the coating during an extended period, the coating remaining intact during implanting, during stent expansion, and during the extended period.

38. A medicated stent comprising:

a stent body,

a biologically active agent,

means for containing and controllably releasing the agent from the stent over an extended period, comprising a first polymer, and

means for bonding the containing means to the stent body, comprising a second polymer,

the containing and bonding means remaining intact upon stent expansion and during the extended period.




Figure 1

BEST AVAILABLE COPY